A novel trial evaluated the impact of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognitive function and BDNF levels in healthy adults. Over a 6-week period, participants received either PEA or a placebo in a double-blinded crossover study. Results indicated a significant rise in serum BDNF levels post-PEA supplementation compared to placebo, alongside enhanced memory performance demonstrated by improved first success and reduced errors on cognitive tests. This study marks the first to demonstrate the cognitive benefits of Levagen+® PEA, suggesting its potential as a valuable intervention for cognitive enhancement, supported by elevated levels of the neurotrophic marker BDNF
Home » Unlocking Cognitive Potential: Palmitoylethanolamide Supplementation Enhances Memory and BDNF Levels in Healthy Adults
Unlocking Cognitive Potential: Palmitoylethanolamide Supplementation Enhances Memory and BDNF Levels in Healthy Adults
Facebook
Twitter
LinkedIn
Email
WhatsApp
Facebook
Twitter
LinkedIn
Email
WhatsApp
Related Shorts
Dietary Zinc Could Lower Endometriosis Risk
November 2, 2024
Grape Seed Extract for Mood Regulation and Cognitive Health
October 24, 2024
Menthol : A Novel Therapeutic Pathway for Alzheimer’s
October 24, 2024
Vitamin D and Probiotics: A New Strategy for Managing Migraines
October 18, 2024
Spermidine: The Polyamine with Potential for a Healthier Heart!
October 18, 2024